# ZUMA-2 (NCT02601313)

> Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02601313
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: Relapsed/Refractory Mantle Cell Lymphoma
- Interventions: brexucabtagene autoleucel; Cyclophosphamide; Fludarabine; Axicabtagene Ciloleucel
- Enrollment: 105
- Primary outcome: Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 1
- Primary outcome: Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 37
- YouTube: 34
- Podcasts: 31

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-2-nct02601313

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02601313", "email": "<work email>"}; the inbox owner confirms by the emailed link.